Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Part of paid clinical trials in San Diego, California.

Sponsor
AstraZeneca
Study ID
NCT00831779
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Tablets, Oral, 5 mg, once daily, 12 weeks
  • Placebo — DRUG
    Tablets, Oral, 0 mg, Once daily, 12 weeks

Study Details

The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity

Key Dates

Start date
Apr 30, 2009
Status verified
Mar 2017
Primary completion
Aug 31, 2010
Completion
Aug 31, 2010

Study Design

Enrollment
116 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
  • Placebo Comparator: Placebo

Primary Outcome Measure

Adjusted Mean Percent Change From Baseline in Insulin Sensitivity at Week 12 (Last Observation Carried Forward [LOCF]) [ Time Frame: From Baseline to Week 12 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Va San Diego Healthcare SystemSan DiegoCalifornia92161-
Pennington Biomedical Research CenterBaton RougeLouisiana70808-
Temple University General Clinical Research CenterPhiladelphiaPennsylvania19140-

Find similar trials in San Diego, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Va San Diego Healthcare System· San Diego, CAPennington Biomedical Research Center· Baton Rouge, LATemple University General Clinical Research Center· Philadelphia, PA

Related Studies